Organization
Senior Department of Oncology
5 abstracts
Abstract
Comparative efficacy of six programmed cell death protein-1 inhibitors in first-line treatment for advanced non-small cell lung cancer: A retrospective cohort study.Org: Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Predictive value of baseline 68Ga‑FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC).Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).Org: Senior Department of Oncology, the 5th Medical Center of the PLA General Hospital, Beijing, China, Medical Affairs Department, 3D Medicines, Shanghai, China,
Abstract
First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Hospital of China Medical University, Shenyang, China, Lung & Gastrointestinal Oncology Department,